Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation

Abstract In non‐small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR‐tyrosine kinase inhibitors. Afatinib, a second‐generation EGFR‐tyrosine kinase inhibit...

Full description

Bibliographic Details
Main Authors: Ayako Morita, Shinobu Hosokawa, Kotaro Yamada, Takahiro Umeno, Hirohisa Kano, Hiroe Kayatani, Masaaki Shiojiri, Makoto Sakugawa, Akihiro Bessho
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Thoracic Cancer
Subjects:
afatinib
dacomitinib
EGFR‐TKI re‐administration
non‐small cell lung cancer
uncommon EGFR mutation
Online Access:https://doi.org/10.1111/1759-7714.13897

Similar Items

Similar Items